查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球毒力敏感市场：应用领域（蔬菜种苗、解毒、毒力治疗、毒力体）、主要地区（北梅、涠洲、亚洲地区）：全球产业趋势预测（2023-2035）
市场调查报告书
商品编码
1398315

全球毒力敏感市场：应用领域（蔬菜种苗、解毒、毒力治疗、毒力体）、主要地区（北梅、涠洲、亚洲地区）：全球产业趋势预测（2023-2035）

Viral Sensitizers Market by Application Area (Viral Vaccines, Oncolytic Viral Therapies, and Viral Vectors) and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2023-2035
出版日期: | 出版商: Roots Analysis | 英文 110 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

至2023年，全球疾病增敏市场规模已达4.81亿元人民币，预测期间（2023-2035年）复合年增长率为14%。

病原体致敏，合成小分子化合物输送到细胞培养基中，减少活细胞系统内部抗病保护，最终增强研究级病原体和病原体治疗生产。 马苏。 近年来，毒力疗法的运用，毒力独特的生物学特性，使医学领域发生了彻底的变化，向医学领域挑战疾病的毒力，成为唯一的致病因子。 病害治疗的综合多治方法，综合苗木活力、降低病苗毒性、双联病苗、利用致病系统基础日本细胞疗法等毒疗法，每种疗法都有各自的作用机制，是否明显影响患者和作者数量目标利润。

製造和毒物处理是一个包含多个步骤的多面向过程。 例如，在高度活跃的内部免疫反应中产生剧毒病原体、剧毒疾病、剧毒疾病、剧毒癫痫、剧毒病原体的复製、剧毒病原体蛋白、外壳和功能性病原体颗粒。 类似的地方，生物对病原体的需求复杂，将哺乳动物细胞培养在适当的培养基中或悬浮，然后将细胞製成颗粒并染色。 病原菌收穫可用于多种树种、综合根部处理、根步细胞治疗、挖菊组、种苗。

产生病原体和病原体的生物繁殖过程中一个重要的挑战是机体生物防御机制的先天防御机制。 内部细胞防御机制负责防止病原体复製，以及根本原因及其相关的蛋白质激活，这是防止病原体复製的重要细胞功能。 翻译后对内在因素的品质和服装的结构进行了修改，造成严重的影响，毒潜力量减少的能力，灵活性受到限制。

为了改善有毒物质的产生，我们开发了一种化学化合物，用于增加疾病的毒性，增加其有效性或增强饲料，并提供补充细胞培养基。 小分子的渗透被暂时禁止，并促进细胞内抗毒素免疫系统的发展。 小分子渗透到细胞内，抑制细胞的传播，并抑制细胞的抗毒素防御机制，利用毒物改变局部感染的效果，并进行繁殖。 此外，由于毒液进入皮质皮肤蛋白质折迭紊乱，促进了少量毒力的存在，这也促进了进一步有效的毒力感染。 除了毒药的临床和商业规模生产外，我们还进行了多种病原体致敏工作，并在实验室进行研究试验以进行疾病控制。

由于无法利用病毒，短期复合市场中短期公司的出现迅速增加。

本报告分析了全球疾病敏化市场，提供了所提供的产品概述、最新市场状况、主要促进/阻碍因素、整体市场规模趋势展望以及区域细分。 详细概述当前趋势的主要公司。

主要市场参与者

  • 维里卡生技公司
  • 托克里斯
  • 宝生物
  • 阿尔斯泰姆
  • UniProt
  • OZ 生物科学公司
  • 应用生物材料
  • 维龙基生物科学公司
  • 美天旎生物科技
  • 赛瑞安生物科技
  • 博卡科学
  • 系统生物科学
  • 米鲁斯生物
  • 富士软片欧文科学公司
  • 赛默飞世尔科技

目录

第一章前言

第二章分析方法

第 3 章经济学和其他计划具体考虑因素

第四章：剧毒致敏加工产业：市场情势

  • 分析概述
  • 药物敏化剂製造商：市场状况

第 5 章市场影响分析：驱动因素、限制、机会、挑战

  • 分析概述
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
  • 结论

第六章全球疾病敏感市场

  • 分析概述
  • 预测方法及金钥安装
  • 全球疾病敏化市场：过去趋势（2020-2022）与未来预测（2023-2035）
  • 主要细分市场
  • 动态桌板

第七章毒力敏感度市场：伊集区划分

  • 分析概述
  • 预测方法及金钥安装
  • Kitabi：过去的趋势（2020-2022）和预测（2023-2035）
  • Kizhou：过去的趋势（2020-2022）与预测（2023-2035）
  • Attai地区：过去的趋势（2020-2022）与预测（2023-2035）
  • Sumometric 调查

第八章疾病敏感市场

  • 分析概述
  • 预测方法及金钥安装
  • 病虫害致敏市场：过去趋势（2020-2022）与预测（2023-2035）
  • Sumometric 调查

第 9 章：治疗性毒物致敏市场

  • 分析概述
  • 预测方法及金钥安装
  • 可溶性结核病治疗毒物成长市场：过去趋势（2020-2022）日本预测（2023-2035）
  • Sumometric 调查

第十章重型疫苗病毒体质病敏市场

  • 分析概述
  • 预测方法及金钥安装
  • 长类流行性苗木病毒性成长市场：过去趋势（2020-2022）与预测（2023-2035）
  • Sumometric 调查

第 11 章 - 细胞治疗的基本疾病敏感药物市场

  • 分析概述
  • 预测方法及金钥安装
  • 基于细胞疗法和病原体致敏市场：过去的趋势（2020-2022）日本预测（2023-2035）
  • Sumometric 调查

第 12 章治疗性有毒药物市场基础

  • 分析概述
  • 预测方法及金钥安装
  • 基于治疗性病原体和物理病原体致敏市场：过去的趋势（2020-2022）日本预测（2023-2035）
  • Sumometric 调查

第十三章结论

第 14 章附录 1：目录

第 15 章附录 2：公司与组织名称

简介目录
Product Code: RA100463

Title: Viral Sensitizers Market: Distribution by Application Area (Viral Vaccines, Oncolytic Viral Therapies and Viral Vectors) and Key Geographical Regions (North America, Europe and Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035.

The global viral sensitizers market is valued at USD 481 million in 2023 growing at a CAGR of 14% during the forecast period 2023-2035.

Viral sensitizers, synthetic small-molecule compounds, are incorporated into cell culture media to diminish the antiviral defenses within production cell lines, ultimately enhancing the production of research-grade viruses and virotherapies. In recent years, virotherapies have transformed the medical field by leveraging the unique biological attributes of viruses, challenging the conventional view of viruses solely as disease-causing agents. Virotherapies encompass a range of treatment approaches, including live, attenuated, and recombinant vaccines, viral vector-based gene and cell therapies, and oncolytic viral therapies, each offering distinct benefits to patients through their unique mechanisms of action.

The manufacturing of these viral therapies is a multifaceted process involving multiple stages. For example, the production of live or attenuated viral vaccines, designed to activate in vivo immune responses, entails viral genome replication, production of viral proteins and capsids, and the assembly of functional viral particles. Similarly, viral vector manufacturing involves intricate procedures, beginning with the cultivation of adherent or suspension mammalian cells in suitable media, followed by cell transfection using plasmid formulations. The harvested viral vectors are then formulated for various applications, including gene therapy, gene-modified cell therapy, and recombinant vaccines.

A significant challenge faced by viral medicine and vaccine manufacturers during bioproduction is the innate defense mechanisms in virus/viral vector-producing cells that respond to pathogens. This intrinsic cellular defense mechanism, triggered by antiviral signaling, leads to the activation of genes and corresponding proteins that disrupt essential cellular functions to hinder viral replication. This can have a substantial impact on the quality of genomes within vectors and the post-translational modifications to the capsid structure, resulting in reduced viral production yields and scalability limitations.

To optimize the manufacturing of viral medicines, synthetic compounds known as viral sensitizers, enhancers, or feed enhancers have been developed for supplementation in cell culture media. These small molecules enhance virus production by temporarily disabling the antiviral immune system in cells. These molecules operate by suppressing the antiviral defense mechanisms in cells through the alteration of cell signaling pathways, allowing viruses to infect, transduce, and replicate more effectively. Additionally, some viral enhancers are designed to facilitate viral penetration of the cortical actin barrier, expediting more efficient viral infection. In addition to their use in clinical and commercial-scale viral medicine manufacturing, several viral sensitizers are available as research reagents for laboratory studies involving virus transduction.

As the applications of viral sensitizers continue to expand, the market for these compounds is expected to experience significant growth in the foreseeable future.

Report Coverage:

  • A systematic research methodology employed for the study on the pulsed field ablation market, offering insights into the assumptions, methodologies, and quality control measures used to ensure the accuracy and reliability of the findings.
  • An overview of the economic factors affecting the overall pulsed field ablation market, including historical trends, currency fluctuations, foreign exchange impacts, recessions, and inflation measurements.
  • An overview of the current market landscape for viral sensitizers/enhancers manufacturers. This overview considers relevant parameters such as the year of establishment, company size in terms of employee count, headquarters location (North America, Europe, and Asia-Pacific), the type of developer (industry and non-industry), and company ownership (privately held and publicly listed).
  • A comprehensive analysis of the factors influencing the growth of the viral sensitizers market. It includes the identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
  • A detailed market forecast analysis, estimating the current market size and future opportunities for viral sensitizers/enhancers from 2023 to 2035. The report also outlines the distribution of historical, current, and forecasted opportunities within the viral sensitizers market. To account for uncertainties and enhance the model's robustness, three forecast scenarios are provided: conservative, base, and optimistic, representing different growth trajectories for the industry.
  • Detailed projections of the historical, current, and future viral sensitizers market across different geographical regions, namely North America, Europe, and Asia-Pacific.
  • Detailed projections of the historical, current, and future viral sensitizers markets for specific applications, including viral vaccines, oncolytic viral therapies, recombinant vaccine-based viral vectors, cell therapy-based viral vectors, and gene therapy-based viral vectors.
  • Summary of the entire report, highlighting key insights into contemporary market trends and the anticipated evolution of the viral sensitizers market based on the research and analysis.

Key Market Companies:

  • Virica Biotech
  • Tocris
  • Takara Bio
  • ALSTEM
  • UniProt
  • OZ Biosciences
  • Applied Biological Materials
  • Virongy Biosciences
  • Miltenyi Biotech
  • SIRION Biotech
  • Boca Scientific
  • System Biosciences
  • Mirus Bio
  • FUJIFILM Irvine Scientific
  • Thermo Fisher Scientific

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1 Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1 Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Future Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impacton Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and PotentialImpact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. VIRAL SENSITIZER MANUFACTURERS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Viral Sensitizer Manufacturers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Type of Player
    • 4.2.5. Analysis by Company Ownership

5. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIESAND CHALLENGES

  • 5.1. Chapter Overview
  • 5.2. Market Drivers
  • 5.3. Market Restraints
  • 5.4. Market Opportunities
  • 5.5. Market Challenges
  • 5.6. Conclusion

6. GLOBAL VIRAL SENSITIZERS MARKET

  • 6.1. Chapter Overview
  • 6.2. Forecast Methodology and Key Assumptions
  • 6.3. Global Viral Sensitizers Market, Historical Trends (2020-2022) and Future Estimates (2023-2035)
    • 6.3.1. Scenario Analysis
  • 6.4. Key Market Segmentations
  • 6.5. Dynamic Dashboard

7. VIRAL SENSITIZERS MARKET, BY GEOGRAPHY

  • 7.1. Chapter Overview
  • 7.2. Forecast Methodology and Key Assumptions
  • 7.3. North America: Historical Trends (2020-2022) and Forecasted Estimates (2023-2035)
  • 7.4. Europe: Historical Trends (2020-2022) and Forecasted Estimates (2023-2035)
  • 7.5. Asia-Pacific: Historical Trends (2020-2022) and Forecasted Estimates (2023-2035)
  • 7.6. Data Triangulation
    • 7.6.1. Insights from Primary Research
    • 7.6.2. Insights from Secondary Research
    • 7.6.3. Insights from In-house Repository

8. VIRAL SENSITIZERS MARKET FOR VIRAL VACCINES

  • 8.1. Chapter Overview
  • 8.2. Forecast Methodology and Key Assumptions
  • 8.3. Viral Sensitizers Market for Viral Vaccines: HistoricalTrends (2020-2022) and Forecasted Estimates (2023-2035)
  • 8.4. Data Triangulation
    • 8.4.1. Insights from Primary Research
    • 8.4.2. Insights from Secondary Research
    • 8.4.3. Insights from In-house Repository

9. VIRAL SENSITIZERS MARKET FOR ONCOLYTIC VIRAL THERAPIES

  • 9.1. Chapter Overview
  • 9.2. Forecast Methodology and Key Assumptions
  • 9.3. Viral Sensitizers Market for Oncolytic Viral Therapies: Historical Trends (2020-2022) and Forecasted Estimates (2023-2035)
  • 9.4. Data Triangulation
    • 9.4.1. Insights from Primary Research
    • 9.4.2. Insights from Secondary Research
    • 9.4.3. Insights from In-house Repository

10. VIRAL SENSITIZERS MARKET FOR RECOMBINANT VACCINE-BASEDVIRAL VECTORS

  • 10.1. Chapter Overview
  • 10.2. Forecast Methodology and Key Assumptions
  • 10.3. Viral Sensitizers Market for Recombinant Vaccine-based Viral Vectors: Historical Trends (2020-2022) and Forecasted Estimates (2023-2035)
  • 10.4. Data Triangulation
    • 10.4.1. Insights from Primary Research
    • 10.4.2. Insights from Secondary Research
    • 10.4.3. Insights from In-house Repository

11. VIRAL SENSITIZERS MARKET FOR CELL THERAPY-BASED VIRAL VECTORS

  • 11.1. Chapter Overview
  • 11.2. Forecast Methodology and Key Assumptions
  • 11.3. Viral Sensitizers Market for Cell Therapy-based Viral Vectors: Historical Trends (2020-2022) and Forecasted Estimates (2023-2035)
  • 11.4. Data Triangulation
    • 11.4.1. Insights from Primary Research
    • 11.4.2. Insights from Secondary Research
    • 11.4.3. Insights from In-house Repository

12. VIRAL SENSITIZERS MARKET FOR GENE THERAPY-BASED VIRAL VECTORS

  • 12.1. Chapter Overview
  • 12.2. Forecast Methodology and Key Assumptions
  • 12.3. Viral Sensitizers Market for Gene Therapy-based Viral Vectors: Historical Trends (2020-2022) and Forecasted Estimates (2023-2035)
  • 12.4. Data Triangulation
    • 12.4.1. Insights from Primary Research
    • 12.4.2. Insights from Secondary Research
    • 12.4.3. Insights from In-house Repository

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION